KDventures AB said Organon has discontinued development of a preclinical drug candidate for polycystic ovary syndrome (PCOS) that was included in Organon’s 2021 acquisition of KDventures’ former portfolio company Forendo. KDventures noted that Organon had already halted development in July 2025 of OG-6219, the most advanced candidate targeting endometriosis, meaning development of both candidates from the acquisition has now stopped. As a result, KDventures will write down to zero the entire remaining book value of its share of the agreement on potential earn-out payments, which will be reflected in its first-quarter 2026 interim report.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. KDventures AB published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603030449OMX_____CNEWS_SV_GNW1001167867_sv) on March 03, 2026, and is solely responsible for the information contained therein.